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Abstract
Background: Chronic pain is common in Europe and elsewhere and its under treatment confers a substantial
burden on individuals, employers, healthcare systems and society in general. Indeed, the personal and
socioeconomic impact of chronic pain is as great as, or greater, than that of other established healthcare priorities.
In light of review of recently published data confirming its clinical and socioeconomic impact, this paper argues
that chronic pain should be ranked alongside other conditions of established priority in Europe. We outline
strategies to help overcome barriers to effective pain care resulting in particular from deficiencies in education and
access to interdisciplinary pain management services. We also address the confusion that exists between proper
clinical and scientific uses of opioid medications and their potential for misuse and diversion, as reflected in
international variations in the access to, and availability of, these agents.
Discussion: As the economic costs are driven in part by the costs of lost productivity, absenteeism and early
retirement, pain management should aim to fully rehabilitate patients, rather than merely to relieve pain.
Accredited education of physicians and allied health professionals regarding state-of-the-art pain management is
crucial. Some progress has been made in this area, but further provision and incentivization is required. We support
a tiered approach to pain management, whereby patients with pain uncontrolled by non-specialists are able to
consult a physician with a pain competency or a specialist in pain medicine, who in turn can recruit the services of
other professionals on a case-by-case basis. A fully integrated interdisciplinary pain service should ideally be avail-
able to patients with refractory pain. Governments and healthcare systems should ensure that their policies on
controlled medications are balanced, safeguarding public health without undue restrictions that compromise
patient care, and that physician education programmes support these aims.
Summary: Strategic prioritization and co-ordinated actions are required nationally and internationally to address
the unacceptable and unnecessary burden of uncontrolled chronic pain that plagues European communities and
economies. An appreciation of the ‘return on investment’ in pain management services will require policymakers to
adopt a long-term, cross-budgetary approach.
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Background
Chronic pain is common in Europe and elsewhere and
its under-treatment confers a substantial burden on
individuals, employers, healthcare systems and society in
general [1-4]. International resolutions have declared
adequate pain therapy to be a human right [5-7] and
chronic pain has been raised as a bioethical issue [8],
and yet untreated chronic pain is under-recognized
by health policymakers as a serious chronic health
problem [5].
In this paper we argue that chronic pain should be
ranked alongside other conditions of established priority
in Europe, in light of recent data confirming its clinical
and socioeconomic impact. We outline strategies, from a
public health perspective, to help overcome barriers to
effective pain care resulting in particular from deficien-
cies in education and access to interdisciplinary pain
management services [9]. We also address the evident
confusion that exists between the proper clinical and
scientific uses of opioid medications and their potential
for misuse and diversion, as reflected in international
variations in the access to, and availability of, these
agents. This paper is based on literature identified from
the Pubmed database using various combinations of
search terms appropriate to the aspect of pain medicine
concerned, including ‘chronic pain’, ‘cost of illness’,
‘economic’, ‘socioeconomic, ‘education’, ‘opioids’, ‘treatment’,
‘multidisciplinary’. We prioritized papers according to their
relevance and newness.
Chronic pain is a leading health and socioeconomic
problem
Chronic pain is common
In 2003, almost one in five surveyed Europeans reported
having moderate or severe chronic pain, defined as pain
lasting at least 6 months duration and with moderate to
severe pain being experienced in the last month and at
least twice a week [1]. This proportion varied from 12%
in Spain to 30% in Norway. Almost 90% of individuals
with chronic pain had experienced it for over 2 years
and yet a third of sufferers were currently not being
treated. The most common sites of pain were the back
and joints, followed by head and neck pain, and com-
mon causes were spinal problems, pain after trauma and
surgery [1]. More recent population-based surveys in
various countries — including Spain [10], Portugal [11],
Ireland [12], Denmark [13], Norway [14] and Iceland
[15] — have consistently estimated that 25–35% of
adults report chronic pain (Table 1). Notably, these stud-
ies did not use a common definition of chronic pain,
such as that of the International Association for the
Study of Pain [16]. An age-standardized analysis of 18
national surveys involving approximately 42,000 adults
found that 37% of respondents in developed countries,
and 41% in developing countries, reported a chronic
pain condition [2]. In Europe, rates exceeded 40% in
Italy, France and Ukraine. Differences between pain
prevalence rates may partly reflect differences in the
definitions of chronic pain used, in severity of pain in-
cluded, and in selection of subjects (the most elderly and
infirm persons, including those living in nursing homes,
are often not included).
Chronic pain is more common among manual workers
and the unemployed than among professional workers
[12], and more common among recipients of social as-
sistance than the general population [17]. Chronic pain
becomes more common with increasing age, especially in
elderly women [1,2,11-14]. Elderly patients in pain are com-
monly undertreated or, more seriously, inappropriately
treated in hospitals and nursing homes [18,19] — settings
generally excluded from population-based surveys. In Italy,
for example, pain was present in almost two thirds of pa-
tients (n = 367) in hospital geriatric departments; only 49%
of these patients were receiving adequate pain therapy [18].
Across Europe, pain was reported in around third of nurs-
ing home residents [19] and inadequate pain control was
the second most common deficiency identified in elderly
home care [20]. The prevention and effective management
of chronic pain in the elderly will be increasingly important
as the population ages.
Half of all cancer patients, and up to 80% of those at
advanced or terminal stages, experience chronic pain
[13,21-24]. Around half of patients with cancer pain are
undertreated [25,26]. Perhaps less well recognised are
the high rates of chronic pain among people with other
comorbid conditions. Indeed, new data suggest that pain
may be at least as common in patients with cardiovascu-
lar disease, chronic pulmonary disease and chronic renal
disease as in those with cancer [13,27].
Chronic pain impairs quality of life, work and functioning
Chronic pain markedly decreases individuals’ health sta-
tus and quality of life (QoL) [10,11,28-31] and can detri-
mentally affect the families of patients [32]. The degree
of this effect is grossly underestimated. Patients admitted
to a multidisciplinary pain centre in Norway reported
health-related QoL as poor as that in patients with ad-
vanced cancer under palliative care [28]. Chronic pain is
consistently linked with an increased risk of depression
[10,12,33-35].
Chronic pain often interferes with everyday activities,
such as family and home responsibilities, recreational ac-
tivities (including exercise) and sleep [1,11,12,26]. At
least half of people with chronic pain report that it inter-
feres with their work [1,11,26]. Across Europe, almost
one in five surveyed patients with chronic pain reported
having lost their job because of their pain and one third
reported that the hours they work, or whether they work
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Table 1 Prevalence of chronic pain in epidemiological studies among adults in selected studies in Europe
Country and survey year Europe and Israel, 20031 [1] Denmark, 2010 [13] Iceland, 2003 [15] Ireland, 2008 [12] Norway, 2006–2008 [14] Portugal, 2007–8 [11]
Survey method Telephone Postal or online Postal Postal Postal Telephone
Sample source and size Telephone directories
(n = 46,394)
National Danish Health
Survey (n = 14,925)
National registry of
general population
(n = 599)
33 general practices
(n = 1204)
Total regional adult
population (n = 4782)
Telephone directories
(n = 5094)
Chronic pain definition2 ≥6 months duration, moderate
or severe, and pain experienced
in the last month and at least
twice a week
≥6 months duration >3 months duration >3 months duration Moderate to severe pain
(SF-8) in at least three of
five consecutive 3-monthly
measurements
≥3 months duration
Prevalence of chronic
pain (95% CI)
All: 19% (ND) All: 26.8% (26.1–27.5%) All: 30.6% (ND) Non-cancer: 35.5% (32.8–38.2%) 31% (30–33%) All: 36.7% (35.3–38.2%)
(12% in Spain to 30% in Norway) Non-cancer: 24.7% (ND)
Prevalence higher in Women, older age Women, older age, various
co-morbidities, non-Western
background,3 underweight
or obese
ND Older age, manual
workers, unemployed
Women, older age, lower
educational level, lower
household income,
higher BMI
Women, older age
retired, unemployed,
lower educational level
BMI, body mass index; CI, confidence intervals; ND, no data; SF-8, Short-Form 8 health survey.
1Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Israel, Italy, the Netherlands, Norway, Poland, Spain, Sweden, Switzerland and the UK.
2The International Association for the Study of Pain (IASP) defines chronic pain as that lasting more than 3 months [16].
3As determined by the birthplace and citizenship of the respondent and the parental birthplace.
Breivik
et
al.BM
C
Public
H
ealth
2013,13:1229
Page
3
of
14
http://w
w
w
.biom
edcentral.com
/1471-2458/13/1229
at all, is affected by their pain [1]. Neuropathic pain may
have a particularly severe impact on work [36]. Import-
antly, chronic pain can last many months, or indeed
many years [1]. A recently published systematic review
revealed that approximately two thirds of patients with
non-specific lower back pain still experience pain 1 year
after its onset, contrary to a commonly held belief that
this normally resolves spontaneously in most patients
[37]. In Finland, researchers found that chronic pain
accounted for up to 30% of medically certified absence
lasting more than 2 weeks [38] and that it was independ-
ently associated with early retirement due to disability
[39]. Other studies have also documented the contribu-
tion of chronic pain to early retirement and disability
pensions [40,41].
Chronic pain: as costly as other prioritized diseases?
Recent studies [30,41-43] have confirmed previous evi-
dence of the enormous indirect socioeconomic costs due
to chronic pain [4,38,44-47]. In the US, the total costs
associated with persistent pain in adults are now esti-
mated at $560–635 billion (2010 prices) [42]. These
costs are reported to exceed those estimated for heart
disease ($309 billion), cancer ($243 billion) and diabetes
($188 billion) [42], although methodological differences
limit the comparability of these values. In Europe,
national healthcare and socioeconomic costs of condi-
tions associated with chronic pain run into billions
annually and represent 3–10% of gross domestic product
(Table 2) [30,41,43]. Direct healthcare costs and indirect
costs each account for approximately half of the total costs,
with some international variation (Table 2). Hospitalization
is the largest single component of direct costs, while social
benefits (e.g. disability allowance and unemployment bene-
fits) make the biggest single contribution to indirect costs
[30,40]. In Sweden in 2008, for example, indirect costs of
sick leave longer than 15 days and early retirement
accounted for 59% of the total costs in patients with
diagnoses related to chronic pain, followed by outpatient
care and inpatient care [43].
Among the types of pain, back pain conditions, cancer
and neuropathies appear most costly (Figure 1) [43,47].
In Germany, societal costs of back pain have been esti-
mated at €16.5–€50 billion when results from multiple
studies are converted to 2008 prices. The bulk of this
cost resulted from the impact of the condition on work
[49]. In Portugal, the total indirect cost of chronic back
and joint pain in 2008 was estimated at approximately
€740 million, with productivity losses estimated at 0.5%
of GDP [50].
Collectively, these data suggest that chronic pain states
and the conditions with which they are associated present a
burden at least as great, or perhaps even greater, than con-
ditions that are conventionally prioritized as public health
concerns. Productivity losses, absenteeism and early retire-
ment and disability retirement contribute substantially to
these costs, and would be best reduced by investment in
improved diagnostic and therapeutic interventions that
promote rehabilitation.
Importantly, these cost estimations are hampered by
the difficulty in identifying patients with chronic pain
within public health and health insurance registries. The
International Classification of Diseases (ICD)-10 system
does not have an adequate and distinct diagnostic code
for chronic pain, although such a code has been created
in Germany [51]. It is to be hoped that the ICD-11 sys-
tem, presently under development, better represents
chronic pain and thereby aids future research.
Discussion
How can the many problems regarding chronic pain
be addressed?
The various attitudinal, educational, legislative, bureaucratic
and economic barriers to effective pain management have
been well documented by the World Medical Organization
[6], the World Health Organization (WHO) and others
[24,52]. We believe that at the root of these many problems
are a lack of knowledge and awareness of the huge impact
chronic pain has on quality of life of patients and on health
care resources. Therefore, first we focus on strategies to
tackle important deficiencies in knowledge and skills of
pain management among healthcare professionals, in the
provision of multidisciplinary care and in the availability
and affordability of such care and medications.
Education is key to improving knowledge of the burden
of pain and its management
Pain management should include a thorough assessment
of the type and severity of pain, the underlying causes,
any associated co-morbidities or psychological problems,
and — where necessary — an interdisciplinary thera-
peutic approach that aims both for pain relief and the
restoration of physical, social and emotional functioning.
Limitations in training among non-pain specialist physi-
cians and other health professionals are an important
barrier to improving patient care. For example, recent
survey data confirm that European primary care physi-
cians find chronic non-malignant pain a challenge to
treat [53]. Key aspects of professional education include
evidence-based guidelines and structured under- and
post-graduate education.
Evidence-based guidelines for the management of
chronic pain
The WHO three-step analgesic ladder for cancer pain
relief has been widely influential [54]. The principle of
offering appropriate analgesia in a timely fashion as ar-
ticulated in the WHO ladder for cancer pain remains
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Table 2 Recent studies on economic impact of chronic pain and conditions with which it is associated
Country (pricing year) Ireland (2008) [30] Sweden (2008) [43] Denmark (2010) [41] United States (2010) [42]
Data source Postal survey National and regional healthcare
administrative registries
National administrative healthcare registries Medical Expenditure Panel Survey
Pain definition Chronic pain and conditions it Diagnoses related to chronic pain Pain-intensive diagnoses (n = 1,918,823) Pain limiting ability to work; diagnoses
of joint pain or arthritis; disability limiting
ability to work (n = 20,214)features (n = 140) (n = 837,896)
Total cost/patient/year €5,665 €6,429 Healthcare costs: DKK34,784–208,830/year
(depending on condition), 2010
ND
Type of cost (% of total) Direct healthcare: 52% Direct healthcare: 41% Direct healthcare: 71% Direct healthcare: 47%
Indirect: 48% Indirect: 59% Indirect: 29% Indirect: 53%
National cost estimate/year €5.34 billion €32 billion DKK17.8 billion $560–635 billion
~3% of GDP ~10% of GDP ~4% of GDPa
GDP, gross domestic product; PRIME, Prevalence, Impact and Cost of Chronic Pain; ND, no data.
aNot in original publication. Assumes US GDP in 2010 of US$14.4 trillion [48]).
Breivik
et
al.BM
C
Public
H
ealth
2013,13:1229
Page
5
of
14
http://w
w
w
.biom
edcentral.com
/1471-2458/13/1229
valid today, although the optimal approach remains a
matter of debate and research [55]. The WHO has
recently published guidelines for the management of
persistent pain in children with medical illnesses [56]
and is developing guidelines for non-malignant pain in
adults [57]. Numerous other national and international
guidelines for the pharmacological treatment of non-
cancer and cancer pain exist [58-65]. While some guide-
lines for chronic non-cancer pain are evidence-based,
for example those by Attal et al. on the pharmacological
treatment of neuropathic pain [59], others are based
primarily on expert opinion owing to a lack of well-
designed, randomized and controlled trials in this area.
Impact of guidelines: do they make a difference?
Of course, the impact of guidelines is dependent on
their implementation and levels of adherence among
practitioners, and improving this is an important aim
[66-69]. For example, evidence from the USA [68] and
Europe [69] suggests that many primary care physicians
are non-compliant with guidelines for chronic low
back pain (LBP). Adherence to the WHO cancer pain
guidelines should provide adequate pain control in
the majority of patients [70,71], and yet pain remains
common among cancer patients [25,26]. Researchers
in Norway recently found that approximately 60% of
persistent opioid users with chronic non-malignant
pain receive concomitant regular benzodiazepines or
benzodiazepine-related hypnotics, in conflict with guide-
lines [66].
Evidence from Germany suggests that an active ap-
proach to implementing LBP guidelines, using physician
education interventions and motivational counselling may
be more effective than simple postal dissemination of the
guideline [72,73]. Certainly, guideline implementation and
adherence among practitioners is likely to be aided by en-
hanced collaboration between professional societies and
healthcare providers, policymakers, reimbursement au-
thorities and health technology assessment authorities.
However, further research is required to establish the opti-
mal means of guideline implementation.
Pre- and post-graduate education in pain medicine for
healthcare professionals
Substantial advances have been made in recent years in
the scientific understanding of pain and its origins. One
of the principal challenges in converting this progress
into benefits to patients is the education of healthcare
professionals regarding the optimal diagnosis and man-
agement of an increasingly complex variety of pain syn-
dromes. All physicians should receive a basic education
in pain management at undergraduate level, as recently
re-iterated by the WHO in its 2011-updated recommen-
dations on achieving balance in availability and treat-
ment of pain with opioids [52]. In 2013, the European
Federation of IASP Chapters (EFIC®) published its pain
management core curriculum for European medical
schools [74]. In reality, the provision of undergraduate
pain education varies within and between countries and
important deficiencies have recently been identified [75].
In part, this variation reflects international differences
in the organization and governance of universities. In
Germany, the content of medical education curricula
is defined federally and a pain examination is now
mandatory [76]. The provision of dedicated undergraduate
pain modules is particularly common in France owing to a
central policy [75]. However, standardized requirements are
less feasible in countries where universities independently
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determine their own curricula (e.g. Austria, Norway and
most Nordic countries, Spain, Italy, and Israel).
Specialized post-graduate education is also required to
develop the expertise necessary to effectively manage pa-
tients with chronic pain. Two levels of post-graduate
education can usefully be distinguished: 1) a diploma-
based competency in pain management available to all
types of physicians, and 2) accreditation of fully-fledged,
cross-disciplinary pain medicine specialist qualification
and role. Post-graduate pain management courses are
now available in many countries [77]. In Italy, for
example, a recent law (2010) means that physicians
wanting to work in pain therapy can attain a specialist
post-graduate Masters qualification in pain therapy or
palliative care [Dr Massimo Allegri, personal communi-
cation]. These are likely to be particular useful for gen-
eral practitioners, orthopaedic specialists and medical
oncologists, the groups responsible for managing many
patients with chronic pain [1,26]. In order to ensure high
standards, pain medicine qualifications should preferably
be regulated by regional or European-wide accreditation
of courses, e.g. through the European Union of Medical
Specialists (UEMS) [77], or EFIC. IASP and EFIC are
already active in providing Pain Schools, e-learning re-
sources [78], and grants to support education initiatives
in Eastern Europe [79].
Pain medicine is now recognized as a speciality,
sub-specialty or competency-based training in several
European countries (e.g. Finland, Germany, Ireland,
Israel, Norway, Sweden, UK and others). However, in
many others advanced pain medicine as an area of mod-
ern medicine that requires special training and experi-
ence remains under-recognized among health managers
and policymakers, and within the medical profession it-
self. This may be in part because the true burden of pain
is still poorly documented, and because pain crosses so
many fields of medicine. Only pain specialists have a
patient-centred, multidisciplinary overview of all aspects
of pain management. Pain specialists have important
roles in the development and implementation of local,
national and international guidelines, leading the devel-
opment of pain care services, assessing and improving
the value of pain care services through further research,
advising governments and health authorities with regard
to policy matters affecting pain (e.g. regarding access to
controlled medicines), and leading public education. The
pain field would also benefit from the development of
best practices (e.g. protocols and policies) designed to
raise standards of care. A good example is the guidelines
on diagnosis and management of complex regional pain
syndrome by the UK National Institute of Excellence
(NICE) and Royal College of Physicians [80].
Pain education must also be properly covered within the
under- and post-graduate education of other healthcare
workers, including psychologists, nurses and pharmacists.
In each case this requires interdisciplinary co-operation be-
tween pain societies, professional societies of allied health-
care professionals, educational institutions and healthcare
systems.
Education of patients and the public
Various cognitive and educational barriers among pa-
tients may interfere with pain management by reducing
adherence with treatment regimens [81,82]. Suggested
components of public education include how to prevent
common types of pain, how and when patients should
self-treat pain, when patients should consult a doctor,
what they can expect from therapy and how they can ac-
cess further forms of support. From a public awareness
perspective, it is important to stress that severe chronic
pain is not acceptable and is not a part of normal
ageing.
The provision of pain education for patients varies
internationally. Efforts to improve this situation include
an initiative to provide collaborative recommendations
on improving education for older adults [83]. EFIC and
IASP run annual Year Against Pain events in an effort to
increase public awareness of pain issues in the public and
media, as well as the medical community (http://www.efic.
org/index.asp?sub=F8AMLHLAP9216P).
Patient education or coaching measures helped to im-
prove pain, functioning, well-being and therapy adher-
ence in some studies in patients with LBP [84,85] and
cancer pain [86-88]. However, a recent systematic review
concluded that the available data on education interven-
tions in LBP were of low quality and showed no
intermediate- or long-term effect on pain and disability
compared with active non-educational interventions
[89]. Mass media campaigns based on education alone
are unlikely to result in positive and persisting behav-
ioural change and need to be supported by other ap-
proaches, for example based on social marketing, policy
and legislation [90]. In Norway, a mass media campaign
on LBP (involving written educational materials sent to
all households, television, radio and cinema advertise-
ments and posters in health clinics) had only a limited
effect on the beliefs of survey respondents among the
general public, as compared with controls not exposed
to the campaign [67,91]. Furthermore, it did not signifi-
cantly affect sickness behaviour (i.e. sickness absence,
surgery rates for intervertebral disc herniation and im-
aging examinations) or change the beliefs of physicians,
physiotherapists and chiropractors regarding LBP, even
though an additional educational initiative was directed at
these groups [92]. These results suggest that a considerable
investment would be needed to improve public understand-
ing and behaviour with regard to chronic pain.
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How can pain management services be optimized?
Interdisciplinary pain management
Ideally, patients with uncontrolled chronic pain should
have access to a full range of diagnostic and therapeutic
modalities appropriate to their case, which may include
pharmacological therapy, physiotherapy, clinical psych-
ology, surgery, invasive techniques, occupational therapy
and rehabilitation medicine. Current data suggest that
access to integrated interdisciplinary pain management
varies across Europe. In Norway, for example, patients
now have a legal right to receive prioritized healthcare
in multidisciplinary pain clinics if their health-related
QoL is severely affected by the pain condition and effica-
cious and cost-effective treatment is available [93]. In
Italy, a law passed in 2010 defined patients’ rights to
access to multidisciplinary pain centres and promoted
the development of regional and national networks of
centres and care pathways [94,95]. In contrast, patients
in many countries have limited access to these services,
and even where multidisciplinary pain centres do exist
there can be prolonged waiting times.
Evidence suggests that adding additional interventions
such as advice, education, exercise, rehabilitation or oc-
cupational therapy to usual care provided by general
practitioners is cost-effective from a societal perspective,
i.e. when loss of earnings and productivity losses are
taken into account [96,97]. Comprehensive multidiscip-
linary assessment and management programmes are
costly and there have been few well-designed evaluations
with long-term follow-up. The available studies are hetero-
geneous, of variable quality, and offer only limited evidence
for an intermediate or long-term benefit or for cost-
effectiveness [89,98-100]. Positive reports from Denmark
[99,101,102] and Sweden [96] on a multi-professional
approach to chronic non-cancer pain are supported by
outcome data from a programme in Germany (preliminary
data published in non-peer reviewed articles in the German
language) [103,104]. In Finland, 46% of 439 patients had
improved QoL after 6 months’ treatment in a multidiscip-
linary pain clinic, and benefits were shown to last for at
least 3 years [105,106]. A randomized 12-month study in
Spain showed significant benefits of multidisciplinary care
in patients with fibromyalgia [107].
Thus, although there is considerable support for the
cost-effectiveness of interdisciplinary management of
complex chronic pain conditions, there is a pressing
need for large, well-designed randomized trials to further
evaluate the effectiveness of chronic pain interventions
and their cost-effectiveness from a societal perspective,
as well as a cost-benefit from the perspective of health-
care providers and patients. The initiation and funding
of projects such as the European Commission-funded
PAIN-OUT project (www.pain-out.eu) is also recom-
mended. This project aims to develop and validate a
system for the continuous measurement, feedback and
benchmarking of treatment quality in postoperative
pain, and to reduce the risk of chronic postoperative
pain with the incorporated European Society of Anaes-
thesiologists project on chronic postsurgical pain
(euCPSP).
Organizing pain management: from general practice to
specialized pain clinics
It is unrealistic to suggest that all patients with chronic
pain should routinely be seen by numerous different
health professionals. Rather, we would define a tiered ap-
proach to pain management that could be applied, with
adaptations, in most countries.
Firstly, general practitioner (GP) or non-specialist phy-
sicians will have to manage most patients with chronic
pain, and hence improvements in the basic pain educa-
tion of this group of doctors are essential. Guidelines for
pain management by GPs are important, but helpful only
if known and accepted by the GPs [68,69]. Secondly, pa-
tients whose pain is not controlled by these professionals
should be referred to an organ or disease specialist ac-
cording to the aetiology of the pain, i.e. to an ortho-
paedic surgeon in the case of hip pain, a neurologist in
the case of headache, and so forth. Referral to physician
with a special pain competency achieved through a post-
graduate qualification, or to a registered pain specialist
or subspecialist, is necessary when a cause is identified
which cannot be reversed by specific medical or surgical
treatment and/or if standard measures prove ineffective.
These physicians should be able to perform a more
detailed, tailored evaluation, to request assistance from
other professionals as appropriate, and to undertake
close monitoring of patients with the adjustment of
therapy as appropriate. Interdisciplinary pain centres
represent the most specialized tier of care, where a
range of professionals with expertise in pain manage-
ment collaborate in a fully integrated, state-of-the-art
service [108]. Importantly, many patients with chronic
pain do not consult a doctor at all [1]. The reasons for
this are unclear and efforts are needed to improve
appropriate healthcare-seeking behaviour among pain
sufferers.
Healthcare decision-makers may under-estimate the
benefits of an interdisciplinary approach to pain man-
agement, or to view them as too nebulous, diffuse,
costly and ineffective. This could result from the lack
of robust data quantifying the burden of pain in rela-
tion to other health problems, and supporting the cost-
effectiveness of physicians with special competence in
pain medicine, as well as interdisciplinary care. Recent
studies discussed above have provided some insight,
but further research is required.
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The importance of savings in social care costs and societal
budgets from pain management programmes
Importantly, the managerial separation (‘ring-fencing’) of
healthcare and social care budgets hinders an appreci-
ation of how, with pain management programmes, the
former are anticipated to be offset by savings in the lat-
ter. A cross-budget approach is therefore required when
evaluating the case for investing in improved pain
management. Furthermore a long-term perspective is
needed owing to the lag between investment in pain
management and prevention and reduced social care
costs [96,102]. Crucially, research is needed to quantify
the effects of improved pain management on absentee-
ism, presenteeism, employment and social care costs. In
Norway, chronic pain is the direct cause of half of the
cases of early or disability retirement [14,40]. This means
that effective treatment and rehabilitation back to work
in only a few of these cases could save a lot of costs in
the social care budgets [40].
Availability of controlled medications for pain: is there a
problem?
Indeed, there is a problem — there being too much
usage of these medications for a few patients, and too
little use (or a lack of availability) for most people in the
world [52].
Pharmacotherapy remains a cornerstone of pain man-
agement, and care quality is compromized if patients
lack access or affordability to recommended prescribed
medications. The availability of medications is limited by
factors such as cost, licensing, prescribing regulations
and cultural factors. These conditions vary widely
between countries, even in Western Europe. Whereas
Austria and north-western European countries have
opioid usage that is second only to the USA and Canada,
an extremely low-use of weak opioids and close to none-
use of potent opioids for chronic non-cancer pain have
recently been documented by an excellent epidemio-
logical study in Portugal [109].
Issues relating to the availability of opioid analgesics,
in particular, have been contentious for many years. In
many countries — especially in Eastern Europe and in
the developing world — access to opioid therapy re-
mains inadequate owing to barriers such as limited sub-
sidy, limited availability, and restrictive regulations on
prescribing and dispensing [24,52,110-113].
Availability and appropriate use of opioids for palliative
care as well as for chronic non-cancer pain
Opioids are the mainstay of treatment of advanced can-
cer pain [54,61,63,64]. They also have a role in selected
patients with chronic, moderate to severe non-cancer
pain, although the evidence base for the efficacy and
safety of long-term opioid therapy is limited [114-116]
and additional well-designed studies are required [117-121].
The only published double-blind, randomized study of an
opioid compared with placebo that lasted as long as
6 months revealed many of the difficulties in performing
blinded, long-term opioid trials, namely those of: maintain-
ing blinding in the presence of typical opioid effects and
side effects, early dropouts in the placebo arm, and potent
and persistent context-sensitive effects of close patient
monitoring by an enthusiastic research pain team [115].
Precautions are necessary to minimize the risks of ad-
verse events, misuse, dependence and misdirection when
opioids are prescribed. These include careful patient
selection with risk assessment, trial therapy periods and
careful monitoring of patients [60,65]. Available trial
data suggest that opioid abuse and addiction are rare
during clinical therapy [120,122]. Nationwide registry
data from Norway suggest that persistent or problematic
use respectively occurred in 0.3% and 0.08% of patients
prescribed weak opioids (e.g. codeine, tramadol and
dextropropoxyphene) for non-cancer pain in clinical
practice [123]. Approximately 0.16% of the general
population persistently use strong opioids on prescrip-
tion, but true “addiction” and abnormal drug-seeking be-
haviour are estimated to represent a small fraction of
this percentage [124]. Further observational research on
such outcomes during therapy with strong opioids used
according to best practice would be helpful [122].
National policies controlling access to opioids differ
widely internationally [125]. Health policymakers tend to
be wary of increasing access to opioids because of fears
and confusion about misuse, misdirection, addiction and
tolerance. In the US, there are concerns that a large in-
crease in opioid use over the last two decades has been
damaging to public health [126]. However, these fears
should not result in reduced access to appropriate thera-
peutic use with careful patient selection and supervision.
The authors urge healthcare decision-makers at all
levels to adopt a balanced approach between ensuring
the availability of controlled medications for legitimate
medical and scientific purposes while preventing their
diversion and abuse, in line with that advocated by the
WHO [52] and the International Narcotics Control
Board [127]. Recent legislation in Italy has simplified the
prescribing of opioids [93,94]. Significant progress has
also been made in some Eastern European countries, e.g.
Romania and Serbia, in replacing restrictive legislation,
improving access and instituting appropriate medical
education [128,129].
Some physicians lack confidence in prescribing opioids,
especially for chronic non-malignant pain [130,131]. Evi-
dence suggests that that education programmes can help to
improve this [132], but changing pain treatment patterns is
challenging [133,134]. Ultimately, prescribing is not the
main difficulty in opioid therapy. Rather, it is essential that
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physicians undertake comprehensive patient and pain
assessment and institute a trial of opioids using pre-
determined outcome measures (e.g. a documented signifi-
cant reduction in pain scores and evidence of improved
physical and psychological functioning). Patients treated
with opioids require careful monitoring, including assess-
ments of early signs of misuse [135]. In light of this, it has
been proposed that opioid therapy for non-cancer pain
should be in the hands of specialists only, not in the hands
of general practitioners. However, this would be difficult to
enforce; improved knowledge among GPs and early referral
of “complex” pain patients to pain specialists may help with
this difficult dilemma. Instead of using a purely pharmaco-
logical focus, under- and post-graduate education on opi-
oids must provide up-to-date instruction on the proper use
of these agents in clinical practice.
Availability and appropriate use of antihyperalgesic
medication
Opioids are not the only analgesic medications that
are often underused. Antihyperalgesic medications for
chronic pain conditions with neuropathic components
(e.g. gabapentin and pregabalin and some antidepres-
sants) are often unavailable or unaffordable. Even when
available, these agents are often not used, or are used in-
appropriately owing to a lack of knowledge of their rec-
ommended place in therapy and how to follow-up the
gradual onset of their therapeutic and adverse effects
[59]. Medical education must therefore cover the range
of agents used in modern pain management and restric-
tions on the availability of all relevant agents should be
subject to the balanced approach discussed above. Pa-
tients must also be informed regarding such aspects as
the anticipated time-course of therapeutic benefits and
adverse effects to help ensure that these agents are used
optimally.
Summary
Strategic prioritization and co-ordinated actions are re-
quired at the national and international levels to address
the unacceptable and unnecessary burden of uncon-
trolled chronic pain that plagues European communities
and economies. The personal and socioeconomic impact
of chronic pain is as great, or greater than, that of estab-
lished healthcare priorities such as cardiovascular disease
and cancer. As the economic costs are driven in part by
the costs of lost productivity, absenteeism and early re-
tirement, pain management should aim to fully rehabili-
tate patients, rather than merely to relieve pain. Chronic
pain must be recognized as a complex somatic and psy-
chosocial disease state (rather than a solely a symptom)
both to allow its epidemiology and impact to be better
quantified and to drive improvements in care. Accredited
education of physicians and allied health professionals
regarding state-of-the-art pain management is crucial.
Some progress has been made in this area, especially with
the availability of post-graduate education in many coun-
tries, but further provision and incentivization is required.
We support a tiered approach to pain management,
whereby patients with pain uncontrolled by non-specialists
are able to consult a physician with a pain competency or a
specialist in pain medicine, who in turn can recruit the ser-
vices of other professionals on a case-by-case basis. A fully
integrated multidisciplinary pain service should ideally be
available to patients with refractory pain, for example in
‘centres of excellence’. Governments and healthcare systems
should ensure that their policies on controlled medications
are balanced, safeguarding public health without undue
restrictions that compromize patient care, and that phys-
ician education programmes support these aims. An appre-
ciation of the ‘return on investment’ in pain management
services will require policymakers to adopt a long-term,
cross-budgetary approach.
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